Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Lymphocyte Count Correlated to Comorbid Diabetes and COVID-19

By LabMedica International staff writers
Posted on 03 Sep 2020
The coronavirus disease (COVID-19) that erupted in China since December 2019 and has gradually spread throughout the world. More...
At present, it has caused tens of thousands of deaths, and the efficacy of certain antiviral drugs is still under review.

Patients with diabetes are more prone to disease progression than those without diabetes; however the mechanism is not yet clear. Depending on the region, 20% to 50% of patients affected by the COVID-19 pandemic had diabetes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a reduction in the lymphocyte count of COVID-19 patients.

Medical scientists at the Nanjing Medical University (Wuxi, China) included in a study 63 adult patients with COVID-19 who were admitted to the hospital from January 29 to March 15, 2020. Patients were classified as having diabetes (n=16) or not having diabetes (n=47). Lymphocytes measured and recorded at admission and during treatment were analyzed and compared between groups. Other outcomes assessed in this study included the number of hospitalization days, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid positive days, and minimal lymphocyte count.

Data pertaining to gender, age, type 2 diabetes mellitus (T2DM) status, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were obtained at the time of admission. Data on alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), and fasting glucose were obtained the next morning after admission. White blood cell count (WBC), C-reactive protein (CRP) and Lymphocytes were measured at admission and during treatment.

The scientists reported that at time of admission, patients with diabetes had a significantly higher maximal C-reactive protein (91.75 mg/L versus 17.0 mg/L) and fasting glucose (8.81 ± 2.42 mmol/L [158.74 ± 43.6 mg/dL] versus 6.01 ± 1.89 mmol/L [108.3 ± 34.1 mg/dL]). A lower minimal lymphocyte count was observed in patients with diabetes versus without diabetes (0.67 ± 0.36 ×109/L versus 1.30 ± 0.54×109/L, respectively). Additionally, the investigators found that the minimal lymphocyte count occurred significantly earlier in patients with diabetes compared with the non-diabetes group (2.68 ± 2.33 days versus 5.29 ± 4.95 days, respectively). Patients with diabetes and COVID-19 also had longer hospital stays (20.44 ± 5.24 days versus 17.11 ± 4.78 days). A negative correlation was found between the minimal lymphocyte count and both hospital days and SARS-CoV-2 nucleic acid positive days.

The authors concluded that COVID-19 patients with T2DM experience a faster decline in lymphocyte count, have lower lymphocyte count, and longer hospital stay than non-diabetic patients. The lower the lymphocyte count, the longer the hospitalization time and viral nucleic acid positive days. The study was published on August 1, 2020 in the journal Diabetes Research and Clinical Practice.


Related Links:
Nanjing Medical University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.